{"id":"NCT00332189","sponsor":"BioMarin Pharmaceutical","briefTitle":"Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006","officialTitle":"A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2006-06-01","resultsPosted":"2012-11-16","lastUpdate":"2012-11-16"},"enrollment":111,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonuria"],"interventions":[{"type":"DRUG","name":"sapropterin dihydrochloride","otherNames":["Kuvan"]}],"arms":[],"summary":"The objective of this study is to evaluate the safety of long-term treatment with Phenoptin in subjects with phenylketonuria (PKU) who participated in Phase 3 clinical studies with Phenoptin.","primaryOutcome":{"measure":"Tabulation of the Incidence and Frequency of All AEs and SAEs That Occur Throughout the Study.","timeFrame":"Baseline through Final Visit (a Maximum of 30 months) with AEs collected at month 3 and 6 then at 6 month intervals","effectByArm":[{"arm":"Total Patient Population","deltaMin":83.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["21646032"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":111},"commonTop":["Upper respiratory tract infection","Cough","Nasopharyngitis","Vomiting","Pyrexia"]}}